Cell Signaling Technology Logo - Extra Large

Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody #2244

Filter:
  • WB

    Product Specifications

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 185
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody detects ErbB2 only when phosphorylated at tyrosine 1248 and EGFR only when phosphorylated at tyrosine 1173.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1248 of human ErbB2. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).

    Alternate Names

    avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; c-erb B2/neu protein; CD340; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EGF receptor; EGFR; Epidermal growth factor receptor; epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); epidermal growth factor receptor tyrosine kinase domain; erb-b2 receptor tyrosine kinase 1; erb-b2 receptor tyrosine kinase 2; ERBB; erbB-2; ERBB1; ERBB2; HER-2; HER-2/neu; HER1; HER2; herstatin; human epidermal growth factor receptor 2; mENA; Metastatic lymph node gene 19 protein; MLN 19; MLN19; NEU; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; NISBD2; p185erbB2; PIG61; Proto-oncogene c-ErbB-1; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; Receptor tyrosine-protein kinase erbB-1; Receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.